» Articles » PMID: 4956339

Effective Nonliving Vaccine Against Experimental Tuberculosis in Mice

Overview
Journal J Bacteriol
Specialty Microbiology
Date 1966 Mar 1
PMID 4956339
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Ribi, Edgar (Rocky Mountain Laboratory, Hamilton, Mont.), Carl Larson, William Wicht, Robert List, and Granville Goode. Effective nonliving vaccine against experimental tuberculosis in mice. J. Bacteriol. 91:975-983. 1966.-Antituberculosis vaccines were prepared in one of three manners: lyophilized BCG suspended in light mineral oil was disrupted in a Sorvall pressure cell and the "oil disruption product" was collected by centrifugation; BCG was disrupted in water, lyophilized, and worked into a paste with a small amount of oil (about 0.16 ml per 50 mg); BCG was disrupted in water, and the cell wall fraction was isolated, lyophilized, and prepared in an oil paste. These vaccines were suspended in Tween-saline to a concentration of 5 mg/ml and heated at 65 C for 30 min. In protection tests based on pulmonary infection with Mycobacterium tuberculosis H37Rv, the median number of virulent organisms in lung tissue of mice immunized with a few hundred micrograms of these three vaccines was 3 to 4 logs lower than in unvaccinated control mice. A similar dose of viable BCG standard vaccine reduced the lung count 1 to 2 logs below the controls. Protection afforded by nonviable, whole BCG, with or without oil, was of only borderline significance. Since oil-treated fractions containing cell walls produced effective immunity, while the oil-treated protoplasm or whole cells were not active, the protective antigen appeared to be an inner component of the cell wall, exposed when the cell was disrupted, and activated by oil. Extraction of oil from immunogenic disruption products resulted in loss of ability of the products to confer protection against the aerosol challenge, whereas high protection against the conventional challenge by intravenous infection with up to 1.4 x 10(8) cells of M. tuberculosis H37Rv was retained. Retreatment with oil of these nonimmunogenic products restored the immunogenicity if the oil was applied to dried products. The consistent finding that moisture interferes with the enhancement of the vaccine potency by oil suggested that such enhancement may not be the same as that ordinarily produced by water-in-oil emulsions.

Citing Articles

Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.

Agger E Adv Drug Deliv Rev. 2015; 102:73-82.

PMID: 26596558 PMC: 4870161. DOI: 10.1016/j.addr.2015.11.012.


Adjuvant treatment increases the resistance to Mycobacterium avium infection of mycobacteria-susceptible BALB/c mice.

Castro A, Aguas A, Silva M Clin Exp Immunol. 1993; 92(3):466-72.

PMID: 8513578 PMC: 1554779. DOI: 10.1111/j.1365-2249.1993.tb03422.x.


Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins.

Andersen P Infect Immun. 1994; 62(6):2536-44.

PMID: 7910595 PMC: 186542. DOI: 10.1128/iai.62.6.2536-2544.1994.


[Intratumor immunotherapy with BCG cell wall preparations: development of a new therapy approach for head-neck tumors].

Bier J, Kleinschuster S, Bier H, Rapp H Arch Otorhinolaryngol. 1982; 236(3):245-55.

PMID: 7159277 DOI: 10.1007/BF00454216.


Macrophage activation and resistance to pulmonary tuberculosis.

LEFFORD M Infect Immun. 1980; 28(2):508-15.

PMID: 6772560 PMC: 550964. DOI: 10.1128/iai.28.2.508-515.1980.


References
1.
DUBOS R, Schaedler R . Reversible changes in the susceptibility of mice to bacterial infections. I. Changes brought about by injection of pertussis vaccine or of bacterial endotoxins. J Exp Med. 1956; 104(1):53-65. PMC: 2136634. DOI: 10.1084/jem.104.1.53. View

2.
DUBOS R, Schaedler R, Bohme D . Effects of bacterial endotoxins on susceptibility to infection with gram-positive and acid-fast bacteria. Fed Proc. 1957; 16(3):856-7. View

3.
Larson C, WICHT W . Studies of resistance to experimental tuberculosis in mice vaccinated with living attenuated tubercle bacilli and challenged with virulent organisms. Am Rev Respir Dis. 1962; 85:833-46. DOI: 10.1164/arrd.1962.85.6.833. View

4.
YOUMANS A, YOUMANS G . FURTHER STUDIES ON A LABILE IMMUNOGENIC PARTICULATE SUBSTANCE ISOLATED FROM MYCOBACTERIUM TUBERCULOSIS. J Bacteriol. 1964; 87:278-85. PMC: 277004. DOI: 10.1128/jb.87.2.278-285.1964. View

5.
YOUMANS G, YOUMANS A, Kanai K . The difference in response of four strains of mice to immunization against tuberculous infection. Am Rev Respir Dis. 1959; 80:753-6. DOI: 10.1164/arrd.1959.80.5.753. View